TNDM$18.06
$18.03
Chart
Performance
Key Stats
AI TNDM Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralTandem Diabetes Care (TNDM) shows mixed signals. Fundamentally, the company is facing significant revenue declines and profitability challenges. Thematic tailwinds in diabetes technology are present, but execution and market competition remain key concerns. Technical indicators suggest a downtrend, with a recent price surge not yet confirmed by broader market sentiment. Investors should exercise caution and monitor upcoming earnings for signs of operational improvement.
Thematic
Tandem Diabetes Care operates within the growing diabetes technology market, driven by advancements in automated insulin delivery systems and continuous glucose monitoring (CGM) integration. The company's focus on user-friendly, integrated solutions aligns with broader healthcare trends towards personalized and connected devices. However, increased competition and the need for ongoing innovation present challenges.
Fundamental
Tandem Diabetes Care's financial performance has been deteriorating, marked by declining revenues and persistent net losses. While gross margins are acceptable, high operating expenses contribute to negative net income. The company's debt level is significant relative to its cash flow, and free cash flow has been negative in recent periods, indicating financial strain.
Technical
The stock has experienced a recent price increase, but remains in a significant downtrend over the medium to long term. Key technical indicators show mixed signals. While some short-term moving averages are turning upwards, longer-term trends and oscillators suggest caution. The stock is trading below its 50-day and 200-day moving averages, indicating bearish momentum.
| Factor | Score |
|---|---|
| Diabetes Technology Market Growth | 75 |
| Product Innovation & Integration | 70 |
| Competitive Landscape | 55 |
| Regulatory Environment | 65 |
| Wearable & Connected Health Trends | 70 |
| Factor | Score |
|---|---|
| Valuation | 50 |
| Profitability | 10 |
| Growth | 20 |
| Balance Sheet Health | 30 |
| Cash Flow | 35 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Trend Analysis | 30 |
| Momentum | 50 |
| Volume Confirmation | 65 |
| Support & Resistance | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Attractive Price-to-Sales Ratio
The trailing Price-to-Sales (P/S) ratio is 1.4, which is competitive given the company's revenue generation capabilities.
Strong Cash Position
The company has a significant amount of cash and cash equivalents (e.g., $69,234,000 as of 2024Q4), providing financial flexibility.
Bearish Points (9)
Consistent Net Losses
The company has reported net losses for the trailing twelve months (TTM) and for annual periods from 2022-2024, indicating ongoing profitability challenges.
Negative P/E Ratio
The Price-to-Earnings (P/E) ratio is negative (e.g., -6.7 TTM, -25.0 for 2024), which is a common characteristic of unprofitable companies and makes traditional P/E valuation difficult.
Calendar
October 2017
10
Next Dividend Date
August 2025
7
Next Earnings Date
H: $-0.26
A: $-0.40
L: $-0.57
H: 243.22M
A: 238.39M
L: 234.10M
Profile
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Seasonals
Price Target
31.10 USD
The 39 analysts offering 1 year price forecasts for TNDM have a max estimate of 59.00 and a min estimate of 14.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct and primary competitor in insulin pumps and continuous glucose monitoring (CGM) systems, offering comprehensive diabetes management solutions.
Weight: 93
Direct competitor specializing in tubeless insulin pump technology (Omnipod), a key alternative to Tandem's t:slim X2.
Weight: 90
Leading continuous glucose monitoring (CGM) provider; their G-series CGM systems are integrated with Tandem's pumps, making them a crucial partner and a competitor in the broader diabetes tech space.
Weight: 88
Major player in diabetes care with its FreeStyle Libre CGM system, a significant competitor to other CGM technologies.